Brian Guttormsen, MD
Interventional Cardiology · Appleton, WINPI 1629045232
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,272 of the $6,222 with a category attached, or 68.7%. 33 manufacturers reported payments, led by Angiodynamics, Inc. at 29.6% of the total. Reporting peaked in 2019 at $2,202 and has fallen 67.4% since, to $717 in 2025.
Across 144 payments — averaging $43.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$2K
- Heartflow, Inc.$682
- Novartis$535
- Boston Scientific$492
- Medtronic$426
- Abbott$351
- plus $2K from 27 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$150
What the payments were for
- Travel & lodging$1,87030%
- Food & beverage$4,27269%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $1,843 |
| Heartflow, Inc. | 7 | $682 |
| Novartis | 23 | $535 |
| Boston Scientific | 16 | $492 |
| Medtronic(2 entities) | 13 | $426 |
| Abbott | 8 | $351 |
| Penumbra, Inc. | 1 | $149 |
| Abiomed | 5 | $136 |
| Inari Medical, Inc. | 6 | $133 |
| Amgen | 7 | $129 |
| Johnson & Johnson | 7 | $128 |
| E.r. Squibb & Sons, L.L.C. | 2 | $121 |
| AstraZeneca | 6 | $110 |
| Astellas Pharma US Inc | 2 | $95 |
| Edwards Lifesciences | 4 | $90 |
| Inspire Medical Systems, Inc. | 2 | $86 |
| Surmodics, Inc. | 5 | $82 |
| Cleerly, Inc. | 1 | $75 |
| EKOS Corporation | 1 | $66 |
| Amarin Pharma, Inc. | 4 | $60 |
| Novo Nordisk | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Boehringer Ingelheim | 3 | $49 |
| Pfizer | 3 | $46 |
| Biosense Webster, Inc. | 2 | $43 |
| Cardiva Medical, Inc. | 2 | $41 |
| Cvrx, Inc. | 1 | $39 |
| Stryker | 1 | $23 |
| Biocompatibles, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Merck | 1 | $16 |
| United Therapeutics Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$538
- AVVIGO Guidance System$256
- SYMPLICITY G3$170
- Indigo System$149
- COROFLOW$133
- TRICLIP$118
- CAMZYOS$105
How this compares
$6,222 in reported general payments places this provider in the 60th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 789 | $898,018 |
| XareltoRivaroxaban | 131 | $173,740 |
| Repatha SureclickEvolocumab | 115 | $93,456 |
| EntrestoSacubitril/Valsartan | 64 | $80,244 |
| BrilintaTicagrelor | 85 | $73,271 |
| JardianceEmpagliflozin | 48 | $62,317 |
| Praluent PenAlirocumab | 16 | $13,969 |
| Metoprolol Succinate | 469 | $9,299 |
| Dofetilide | 17 | $6,922 |
| Atorvastatin Calcium | 342 | $4,953 |
| Ranolazine ErRanolazine | 27 | $4,016 |
| Furosemide | 463 | $3,815 |
| Spironolactone | 396 | $3,731 |
| Metoprolol Tartrate | 428 | $3,716 |
| Potassium Chloride | 107 | $3,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $898,018789 claims |
| Johnson & JohnsonXarelto | $128 | $173,740131 claims |
| NovartisEntresto | $535 | $80,24464 claims |
| AstraZenecaBrilinta | $110 | $73,27185 claims |
| Boehringer IngelheimJardiance | $49 | $62,31748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Appleton
- Cherian VargheseAppleton$10K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.